Real-world outcomes of Cabozantinib in advanced renal cell carcinoma (CASSIOPE Study)
Dra. María Natalia Gandur Quiroga, Coordinator in charge of the Urology Clinic Service at the Angel H. Roffo Institute, shared a recent article by Michael D. Staehler on X:
“Real-world outcomes of Cabozantinib in advanced renal cell carcinoma (aRCC) (CASSIOPE Study).
Key Findings: Cabozantinib showed effectiveness in real-world advanced RCC settings, with 8.3 months median PFS and a 74% 1-year OS rate.
Dose Adjustments: 77% required dose modifications for AEs, successfully optimizing treatment duration.
Manageable Safety: Safety profile consistent with clinical trials, with diarrhea, decreased appetite, and PPE syndrome as the most common AEs.
Real-world Impact: Demonstrates cabozantinib’s utility for patients excluded from clinical trials, reflecting broader applicability.”
Authors: Michael D. Staehler, Paul Hamberg, Pierre Bigot, Cristina Suárez, Philippe Barthelemy, Jean-Christophe Eymard, Mathieu Laramas, Naila Taguieva Pioger, Marine Gross-Goupil, Michael Rink, Cristina Masini, Rocco De Vivo, Pablo Gajate, Ashraf Azzabi and Giuseppe Procopio
More posts featuring Dra. María Natalia Gandur Quiroga.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023